Extending the window for stroke clot-busting drug
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a clot-dissolving medication called rhTNK-tPA for people who had a stroke 4.5 to 24 hours ago. It aims to help those with certain types of blockages in the brain who are still having moderate to severe symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your stroke symptoms started between 4.5 and 24 hours before treatment.
- You were able to do all your normal activities before the stroke (mRS score 0 or 1).
- You have at least moderate stroke symptoms (NIHSS score of 6 or higher).
- Brain scans show a blockage in a major brain artery and a 'mismatch' where some brain tissue can still be saved.
- You or your legal guardian can sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether tenecteplase (a clot-busting medication) can help patients who have had a stroke within 4.5 to 9 hours and show a specific pattern on brain MRI called DWI-FLAIR mismatch, which suggests the brain tissue may still be salvageable.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.
This trial tests a clot-busting drug for people who had a stroke more than 4.5 hours ago. It uses a special CT scan to see if the treatment can still help them.
This study compares the safety of two FDA-approved clot-dissolving medicines (rhTNK-tPA and rt-PA) given through an IV to patients having an acute ischemic stroke (a stroke caused by a blood clot in the brain). Researchers want to understand which treatment is safer and how well each works.
This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.